In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

Piper Sandler analyst David Amsellem maintained a Buy rating on Indivior (INDV – Research Report) today and set a price target of $16.00. The ...

The stock's fall snapped a two-day winning streak.

Goodman now anticipates that the biotechnology company will post earnings of $16.65 per share for the year, down from their prior estimate of $18.00. The consensus estimate for Biogen’s current ...

Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ ... If that happens, this would mark the best quarter for company profits since 2021. While the overall outlook for ...

OpenAI has rebranded its look with tweaks to its signature blossom logo and a new typeface called OpenAI Sans, hoping to have a more approachable and human image.

Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen reported this week that sales of the drug reached $67 million in the third quarter – including $39 million in the US – which fell short of the company's expectations. It said the ...